Gilead’s Lenacapavir to Reach High-Burden Nations ‘At Cost’
Gilead’s Lenacapavir is set to revolutionise HIV prevention efforts, aiming to protect two million people across affected nations.
Aspen Unlocking Value with New Manufacturing Strategies
Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.
Global Health Crisis and the Threat to NTD Programmes
Uncover the Global Health Crisis caused by the loss of crucial medicines, risking a resurgence of neglected tropical diseases.
Aspen Shares Nosedive 15% on JSE After Shock Profit Warning
Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
Adcock Ingram Reports Flat Profit Despite Winter Surge
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
Novo Nordisk Hiring Freeze After Wegovy Sales Decline
Novo Nordisk implements a hiring freeze as layoffs approach after Wegovy's success. Discover the impact on the pharmaceutical industry.
Regulatory Delays Threaten Africa’s Pharmaceutical Ambition
Regulatory delays are hindering Africa's R1.25-trillion pharmaceutical manufacturing goals and access to markets.
Vertex’s Trikafta: Addressing Drug Pricing Issues
Health activists highlight the issues with Vertex's Trikafta pricing and access, advocating for justice in cystic fibrosis care.
Lower Pharmaceutical Prices: Trump’s Bold Ultimatum
Trump demands lower pharmaceutical prices from major drug companies in a bold move to align US costs with global standards.
Bidvest’s Role in Adcock Ingram Takeover Bid
Learn how Bidvest's partnership with Natco Pharma impacts Adcock Ingram and shareholder rights amid a new takeover bid.